Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial
Authors: Sajobi Tolulope T. , Arimoro Olayinka I. , Ademola Ayoola , Singh Nishita , Bala Fouzi , Almekhlafi Mohammed A. , Deschaintre Yan , Coutts Shelagh B. , Thirunavukkarasu Sibi , Khosravani Houman , Appireddy Ramana , Moreau François , Gubitz Gordon J. , Tkach Aleksander , Catanese Luciana , Dowlatshahi Dar , Medvedev George , Mandzia Jennifer , Pikula Aleksandra , Shankar Jai Shiva , Williams Heather , Field Thalia S. , Manosalva Alejandro , Siddiqui Muzaffar , Zafar Atif , Imoukhuede Oje , Hunter Gary , Demchuk Andrew M. , Mishra Sachin M. , Gioia Laura C. , Jalini Shirin , Cayer Caroline , Phillips Stephen J. , Elamin Elsadig , Shoamanesh Ashkan , Subramaniam Suresh , Kate Mahesh P. , Jacquin Gregory , Camden Marie-Christine , Benali Faysal , Alhabli Ibrahim , Horn MacKenzie , Stotts Grant , Hill Michael D. , Gladstone David J. , Poppe Alexandre Y. , Sehgal Arshia , Zhang Qiao , Lethebe Brendan , Doram Craig , Shamy Michel , Kenney Carol , Buck Brian H. , Swartz Richard H. , Menon Bijoy K. 
Published: January 2024

BACKGROUND:
Recent evidence from thrombolysis trials indicates the noninferiority of intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in patients with acute stroke. We examined whether the health-related quality of life (HRQOL) of patients with acute stroke differs by the type of thrombolysis treatment received. In addition, we examined the association between the modified Rankin Scale score 0 to 1 and HRQOL and patient-reported return to prebaseline stroke functioning at 90 days.

METHODS:

Data were from all patients included in the AcT trial (Alteplase Compared to Tenecteplase), a pragmatic, registry-linked randomized trial comparing tenecteplase with alteplase. HRQOL at 90-day post-randomization was assessed using the 5-item EuroQOL questionnaire (EQ5D), which consists of 5 items and a visual analog scale (VAS). EQ5D index values were estimated from the EQ5D items using the time tradeoff approach based on Canadian norms. Tobit regression and quantile regression models were used to evaluate the adjusted effect of tenecteplase versus alteplase treatment on the EQ5D index values and VAS score, respectively. The association between return to prebaseline stroke functioning and the modified Rankin Scale score 0 to 1 and HRQOL was quantified using correlation coefficient (
r
) with 95% CI.

RESULTS:

Of 1577 included in the intention-to-treat analysis patients, 1503 (95.3%) had complete data on the EQ5D. Of this, 769 (51.2%) were administered tenecteplase and 717 (47.7%) were female. The mean EQ5D VAS score and EQ5D index values were not significantly higher for those who received intravenous tenecteplase compared with those who received intravenous alteplase (
P
=0.10). Older age (
P
<0.01), more severe stroke assessed using the National Institutes of Health Stroke Scale (
P
<0.01), and longer stroke onset-to-needle time (
P
=0.004) were associated with lower EQ5D index and VAS scores. There was a strong association (
r
, 0.85 [95% CI, 0.81–0.89]) between patient-reported return to prebaseline functioning and modified Rankin Scale score 0 to 1 Similarly, there was a moderate association between return to prebaseline functioning and EQ5D index (
r
, 0.45 [95% CI, 0.40–0.49]) and EQ5D VAS scores (
r
, 0.42 [95% CI, 0.37–0.46]).

CONCLUSIONS:
Although there is no differential effect of thrombolysis type on patient-reported global HRQOL and EQ 5D-5L index values in patients with acute stroke, sex- and age-related differences in HRQOL were noted in this study.

REGISTRATION:

URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT03889249.